UNBX (Unity Biotechnology) Marketable Securities: $8.93 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Unity Biotechnology Marketable Securities?

Unity Biotechnology UNBX Marketable Securities is $8.93 Mil as of Mar. 2025.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Unity Biotechnology's Marketable Securities for the quarter that ended in Mar. 2025 was $8.93 Mil.

Unity Biotechnology's annual Marketable Securities declined from Dec. 2022 ($82.06 Mil) to Dec. 2023 ($23.40 Mil) and declined from Dec. 2023 ($23.40 Mil) to Dec. 2024 ($15.65 Mil).

Unity Biotechnology  (OTCPK:UNBX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Unity Biotechnology Marketable Securities Related Terms

Unity Biotechnology Marketable Securities Historical Data

* Premium members only.

The historical data trend for Unity Biotechnology's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unity Biotechnology Marketable Securities Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Marketable Securities
Get a 7-Day Free Trial Premium Member Only 79.89 55.17 82.06 23.40 15.65

Unity Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.90 26.40 20.14 15.65 8.93

Unity Biotechnology Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $8.93 Mil mean?
Unity Biotechnology (UNBX) has a Marketable Securities of $8.93 Mil as of Mar. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Unity Biotechnology and its competitors.
Is Unity Biotechnology's Marketable Securities too high?
Unity Biotechnology's current Marketable Securities is $8.93 Mil.
How does Unity Biotechnology's Marketable Securities compare to ADTX and HEPA?
Unity Biotechnology's Marketable Securities of $8.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Unity Biotechnology and its competitors. Unity Biotechnology's current Marketable Securities is $8.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unity Biotechnology stock overvalued right now?
Unity Biotechnology (UNBX) has a current Marketable Securities of $8.93 Mil. The current Marketable Securities is $8.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Unity Biotechnology (UNBX), the current Marketable Securities is $8.93 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unity Biotechnology Business Description

Address 285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.